According to filings with the U.S. Securities and Exchange Commission, Protuoso Biosciences has raised $9,500,000.00 in new Angel/Seed funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the current round of funding include: Taya Venture and Darwin Ventures, NSG Ventures, SEEDS.

About Protuoso Biosciences
Protuoso Biosciences is a pioneering biotechnology company focused on developing next-generation multifunctional biologics, branded as MUXBODIES, to treat complex diseases with high unmet medical need. Using an integrated platform that combines AI-driven protein engineering, computational protein design, and synthetic biology, the company designs differentiated, modular protein architectures capable of precisely engaging multiple disease mechanisms at once. Protuoso operates a hub-and-spoke model, in which a centralized, therapeutic-agnostic protein engineering hub supports the focused development of multiple assets, enabling parallel innovation, efficient portfolio expansion, and disciplined resource allocation. Its MUXBODIES are engineered to deliver enhanced efficacy and safety by creating synergistic, multifunctional protein formats tailored for complex disease biology, positioning the company to build a broad, scalable therapeutic portfolio. Based in San Carlos, California, Protuoso Biosciences presents itself as a capital-efficient, innovation-driven player aiming to establish a strong market position in next-generation biologics for high-impact therapeutic areas.

To learn more, visit https://www.protuoso.bio/
Linkedin: https://www.linkedin.com/company/protuoso-bio/

Contact:
Willie Xiang, President and COO
https://www.linkedin.com/in/willie-xiang/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.